Skip to content
Review Open access

Cancer-Associated Fibroblasts in Gastric Cancer Peritoneal Metastasis

2026 · Oncology Research · 0 citations · 112 references

Abstract

: Gastric cancer is a leading cause of cancer-related death worldwide; among its progression patterns, peritoneal metastasis (PM) has the poorest prognosis. PM lesions show strong resistance to immune checkpoint inhibitors (ICIs), and the molecular basis of this resistance remains poorly understood. The aim of this review is to clarify how cancer-associated fibroblasts (CAFs) act as master regulators shaping the peritoneal tumor microenvironment (TME); to this end, we integrate four interrelated dimensions: cellular origin, transcriptional diversity, spatial organization, and immunosuppressive mechanisms. First, CAFs in PM arise from diverse lineages, including mesothelial-to-mesenchymal transition (MMT) of peritoneal mesothelial cells, omental adipose-derived stromal cells, bone marrow–derived progenitors, and endothelial-to-mesenchymal transition of vascular endothelium. Second, single-cell RNA sequencing resolves CAFs into transcriptionally distinct subtypes such as myofibroblastic CAFs, inflammatory CAFs, and antigen-presenting CAFs (apCAFs), thus exhibiting plasticity as dynamic cell states that transition in response to environmental signals. Third, spatial multiomics analysis reveals that these subtypes form layered niches within metastatic lesions, with a PM-specific, THBS2-positive, mCAF–SPP1-positive tumor-associated macrophage axis driving immune exclusion and ICI resistance. Fourth, through interleukin-6, CXCL12, and interleukin-17A–STAT3 pathways and incomplete antigen presentation by apCAFs, CAFs establish and maintain a fibrosis-dominant, immunologically cold peritoneal TME. Finally, we summarize the current status and prospects of CAF-targeted therapeutic strategies centered on drug repositioning of antifibrotic agents acting on the MMT axis and outline future challenges to overcome PM refractoriness.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.